Liver disease in injection drug users with hepatitis C, with and without HIV coinfection

Journal of Addictive Diseases

Volumn 27, Issue 2, 2008, Pages 49-59

  Monto, Alexander ^a,c   Currie, Sue ^b   Wright, Teresa L ^b  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b University of Californis   (United States)

^c NONE   (United States)

Author keywords

Cirrhosis; HAART; Hepatitis C; HIV

Indexed keywords

ANTIRETROVIRUS AGENT; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN;

ALCOHOL CONSUMPTION; CD4 LYMPHOCYTE COUNT; DISEASE COURSE; DRUG ABUSE; DRUG EFFICACY; DRUG TOLERABILITY; FATTY LIVER; HEALTH CARE UTILIZATION; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CIRRHOSIS; LIVER DISEASE; MIXED INFECTION; REVIEW; COMORBIDITY; INCIDENCE; PREVALENCE; SUBSTANCE ABUSE;

COMORBIDITY; HEPATITIS C; HIV INFECTIONS; HUMANS; INCIDENCE; LIVER CIRRHOSIS; PREVALENCE; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 52049099901     PISSN: 10550887     EISSN: 15450848     Source Type: Journal    
DOI: 10.1300/J069v27n02_06     Document Type: Review

References (60)

1. Gearing FR, Schweitzer MD. An epidemiologic evaluation of long-term methadone maintenance treatment for heroin addiction. Am J Epidemiol 1974;100: 101-12.
2. Frischer M, Goldberg D, Rahman M, et al. Mortality and survival among a cohort of drug injectors in Glasgow, 1982-1994. Addiction 1997;92:419-27.
3. Hser YI, Hoffman V, Grella CE, et al. A 33-year follow-up of narcotics addicts. Arch Gen Psychiatry 2001;58:503-8.
4. Lorvick J, Kral A, Seal KH, et al. Prevalence and duration of hepatitis C among injection drug users in San Francisco, California. Am J Public Health 2001;91: 46-7.
5. Hahn JA, Page-Shafer K, Lum PJ, et al. Hepatitis C infection and needle exchange use among young injection drug users in San Francisco. Hepatol 2001;34: 180-7.
6. Thomas DL, Shih JW, Alter HJ, et al. Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. J Infect Dis 1996;174:690-5.
7. Sherman KE, Rouster SD, Chung RT, et al. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adults AIDS Clinical Trials Group. Clin Infect Dis 2002;34:831-7.
8. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
9. Mocroft A, Ledergerber B, Katlama C, et al. Decline in AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003;362:22-9.
10. Gebo KA, Fleishman JA, Conviser R, et al. Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. J Acquir Immune Defic Syndr 2005;38:96-103.
11. Lloyd-Smith E, Brodkin E, Wood E, et al. Impact of HAART and injection drug use on life expectancy of two HIV-positive cohorts in British Columbia. AIDS 2006;20:445-50.
12. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;351:438-50.
13. Chung RT, Anderson J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004;351:451-9.
14. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs. standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004;292: 2839-48.
15. Muir AJ, Bornstein JD, Killenberg PG, et al. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004;350:2265-71.
16. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000;90:1562-9.
17. Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: The Swiss HIC Cohort Study. Lancet 2000;356:1800-5.
18. DeLuca A, Bugarini R, Lepri AC, et al. Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naïve HIV-infected subjects. Arch Int Med 2002;162:2125-32.
19. Fattovich G,Pantalena M, Zagni I, et al. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol. 2002;97:2886-95.
20. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatol 2005;42:1208-36.
21. Darby SC, Ewart DW, Giangrande PLF, et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. Lancet 1997;350:1425-31.
22. Pineda JA, Romero-Gomez M, Diaz-Garcia F, et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensataed cirrhosis. Hepatol 2005;41:779-89.
23. BedossaP, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. Hepatol 1996; 24:289-93.
24. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis in patients with chronic hepatitis C. Lancet 1997;349:825-32.
25. Yano M, Kumada H, Kage M, et al. The longterm pathological evolution of chronic hepatitis C. Hepatol 1996;23:1334-40.
26. Gordon SC, Fang JWS, Silverman AL, et al. The significance of baseline alanine aminotransferase on pretreatment disease characteristics and response to antiviral therapy in chronic hepatitis C. Hepatol 2000, 32:400-4.
27. Danta M, Dore G, Hennessy L, et al. Factors associated with severity of hepatic fibrosis in people with chronic hepatitis C infection. Med J Australia 2002; 177:240-5.
28. Poynard T, Ratziu V,Charlotte F, et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001;34:730-9.
29. Adinolfi LE, Gambardella M, Andreana A, et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatol 2001;33: 1358-64.
30. Monto A, Alonzo J, Watson JJ, et al. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatol 2002;36:729-36.
31. Monto A, Patel K, Bostrom A, et al. Risks of a range of alcohol intake on hepatitis C-related fibrosis. Hepatol 2004;39:826-34.
32. Hickman IJ, Clouston AD, Macdonald GA, et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 2002; 51:89-94.
33. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterol 2002;122:1303-13.
34. Benhamou Y, DiMartino V, Bochet M, et al. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatol 2001;34: 283-7.
35. Tural C, Fuster D, Tor J, et al. Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitisC virus (HCV) co-infected patients. J Viral Hepatitis 2003;10:118-25.
36. Martin-Carbonero L, Benhamou Y, Puoti M, et al. Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis 2004;38:128-33.
37. Delladetsima J, Katsarou O, Touloumi G, et al. Significance of immune status, genotype, and viral load in the severity of chronic hepatitis C in HIV infected haemophilia patients. Haemophilia 2002;8:668-73.
38. Mehta SH, Thomas DL, Torbenson M, et al. The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection. Hepatol 2005;41:123-31.
39. Uberti-Foppa C, De Bona A, Galli L, et al. Liver fibrosis in HIV-positive patients with hepatitis C virus. JAIDS 2006;41:63-7.
40. Mohsen AH, Easterbrook PJ, Taylor C, et al. Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut 2003;52:1035-40.
41. Sterling RK, Contos MJ, Sanyal AJ, et al. The clinical spectrum of hepatitis C virus in HIV coinfection. JAIDS 2003;32:30-7.
42. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001;33:562-9.
43. Verma S, Wang CH, Govindarajan S, et al. Do type and duration of antiretroviral therapy attenuate liver fibrosis in HIV-hepatitis C virus-coinfected patients? Clin Infect Dis 2006; 42:262-70.
44. Martinez-Sierra C, Arizcorreta A, Diaz F, et al. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis 2003;36:491-8.
45. Kramer JR, Giordano TP, Souchek J, et al. The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. veterans with hepatitis C. Am J Gastroenterol 2005;100:56-63.
46. DiMartino V, Rufat P, Boyer N, et al. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term, retrospective study. Hepatol 2001;34:1193-9.
47. Marine-Barjoan E, Saint-Paul MC, Pradier C, et al. Impact of antiretroviral treatment on progression of hepatic fibrosis in HIV/hepatitis C co-infected patients. AIDS 2004;18:2163-70.
48. Fuster D, Planas R, Muga R, et al. Advanced liver fibrosis in HIV/HCV-coinfected patients on antiretroviral therapy. AIDS Res Human Retroviruses 2004; 20:1293-7.
49. Schneiderman D, Arenson DM, Cello JP, et al. Hepatic disease in patients with the acquired immune deficiency syndrome (AIDS). Hepatol 1987;7:925-30.
50. Albisetti M, Braegger C, Stallmach T, et al. Hepatic steatosis: a frequent non-specific finding in HIV-infected children. Eur J Pediatr 1999;158:971-4.
51. Fortgang I, Belitsos P, Chaisson R, et al. Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analogue antiretroviral therapy. Am J Gastroenterol 1995;90:1433-6.
52. Brinkman K, ter Hofstede HJ, Burger DM, et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998; 12:1735-44.
53. Sekhar RV, Jahoor F, White AC, et al. Metabolic basis of HIV-lipodystrophy syndrome. Am J Physiol Endocrinol Metab 2002;283:E332-7.
54. Sutinen J, Hakkinen A-M, Westerbacka J, et al. Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy. AIDS 2002;16:2183-93.
55. Ogedegbe A-E, Thomas DL, Diehl AM. Hyperlactatemia syndromes associated with HIV therapy. Lancet Infect Dis 2003;3:329-37.
56. Sulkowski MS, Mehta SH, Torbenson M, et al. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS 2005;19:585-92.
57. Marks KM, Petrovic LM, Talal AH, et al. Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virus. Journal of Infect Dis 2005;192: 1943-9.
58. Monto A, Dove LM, Bostrom A, et al. Hepatic steatosis in HIV- hepatitis Ccoinfection: prevalence and significance compared to hepatitis C monoinfection. Hepatol 2005;42:310-6.
59. Zeuzem S, Sarrazin C, Rouzier R, et al. Anti-viral activity of SCH 503034, a HCV protease inhibitor, administered as monotherapy in hepatitis C genotype 1 patients refractory to pegylated interferon. Hepatol 2005;42:S1, 233-4A.
60. Reesink HW, Zeuzem S, Weegink CJ, et al. Final results of a phase 1b, multiple-dose study of VX-950, a hepatitis C virus protease inhibitor. Hepatol 2005;42: S1, 234-5A.